|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2006-11-1
|
|
pubmed:abstractText |
Patients with severe persistent asthma experience daily symptoms and frequent serious exacerbations that contribute to a significant impairment of health-related quality of life (QoL).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1473-4877
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2201-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17076981-Adolescent,
pubmed-meshheading:17076981-Adult,
pubmed-meshheading:17076981-Aged,
pubmed-meshheading:17076981-Anti-Asthmatic Agents,
pubmed-meshheading:17076981-Antibodies, Anti-Idiotypic,
pubmed-meshheading:17076981-Antibodies, Monoclonal,
pubmed-meshheading:17076981-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17076981-Asthma,
pubmed-meshheading:17076981-Child,
pubmed-meshheading:17076981-Female,
pubmed-meshheading:17076981-Humans,
pubmed-meshheading:17076981-Hypersensitivity,
pubmed-meshheading:17076981-Male,
pubmed-meshheading:17076981-Middle Aged,
pubmed-meshheading:17076981-Quality of Life,
pubmed-meshheading:17076981-Randomized Controlled Trials as Topic,
pubmed-meshheading:17076981-Severity of Illness Index
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Improvement in quality of life with omalizumab in patients with severe allergic asthma.
|
|
pubmed:affiliation |
Capital Allergy and Respiratory Disease Center, Sacramento, California 95819, USA. b.chipps@capitalallergy.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Meta-Analysis
|
